Mon, 14 Sep 2026
Pharma in Focus

Connecting you with your industry every day

Login
Regulation & Legal

Fake Lilly drug causes serious side effect

An Australian patient suffered a torn oesophagus after using the counterfeit, which contained eight times the active ingredient used in a popular drug, sponsored by a rival company

Latest

Funding for CAR-T trials for Aussie kids

The first funding from the Australian Cancer Research Program will assist children and young adults with cancer participate in global CAR-T trials

Latest

Leaders gather for first-ever roundtable

More than 40 leaders gather to accelerate evidence-based action, as diagnoses of gynaecological cancers are set to rise 21 per cent over the next decade

Latest News
Featured

GM ANZ role up for grabs

Pharma launches a recruitment drive to find the company's next leader with a glowing reference from the current GM who is leaving for a new organisation

Leadership & People

Is Medical Affairs the 'Jan Brady' of pharma?

The MAPA Medical Affairs Summit was told MA is like the 'middle child' of pharma in a robust debate about how best the function can unleash its true potential

Regulatory & Reimbursement

$113M Novartis drug under threat

Among a raft of medicines added to the ARTG last week is the first generic of a Novartis drug that earned $113 million in pre-rebate PBS benefits over the past year.

Leadership & People

Scientists behind Big Pharma drugs gonged

Five scientists and a Canadian-American actor behind big name drug discoveries have been recognised for their efforts at the 2026 Lasker Foundation Awards

All positions →

Jobs

  1. Graphic Designer New

    HPGSydneyMarketing
  2. Business Development Executive QLD New

    HPGBrisbaneSales
  3. Quality Assurance Specialist New

    HPGSydneyRegulatory
  4. Medical Marketing Specialist New

    HPGSydneyMarketing
  5. Territory Manager New

    HPGSydneySales
  6. Clinical Database Developer New

    HPGMelbourneClinical
  7. Medical Marketing Specialist New

    HPGSydneyMarketing
  8. Business Development Executive QLD New

    HPGBrisbaneSales
Earlier News
Leadership & People

How to lead without the job title

Medical affairs heavyweights joined a panel at MAPA to outline how people can take the lead in their organisations whatever the title they have

Leadership & People

Another Country Boss departs

After 11 years working for the same Big Pharma and almost four serving on the Board of the industry body, this executive is the latest leadership departure

Regulatory & Reimbursement

Who's won an October PBS listing... already?

Nineteen days before the turn of the calendar, the Govt has announced the PBS listing of a new treatment for patients with a debilitating disease

Latest

US Govt funds access to Aussie drug

Millions in funding will allow up to 200 people to access a drug currently in a Phase 2/3 trial, providing real-world clinical data from a broader population.

Jobs & Workplace

Global boss lands top Aussie role

Relocating to Australia from London, this global value and access high-flyer has been snapped up by J&J for a senior leadership position

Industry & Companies

Company eyes ‘golden decade’

Pharma sets an ambitious goal to establish a portfolio of more than 100 biosimilars by 2040, up substantially from the 13 it currently markets

Regulatory & Reimbursement

Butler tips more drugs to follow the 'Beast’

The Health Minister is “very confident” that other immunotherapy drug makers will submit broad PBS listing submissions following in the footsteps of a drug he referred to as the 'Beast' which has just won multi-cancer reimbursement

Industry & Companies

Industry body names new leader

After 12 years, this well-known leader who has worked tirelessly for equity in cancer care is standing down with a successor already named

Featured

Meet ANZ's best Medical Affairs professionals

Thirteen medical affairs professionals, some representing their teams, have been recognised for their outstanding contribution to the industry across Australia and New Zealand

More News
Industry & Companies

On the edge: Here comes the $550B cliff fall

An industry-wide upheaval is coming to pharma with a monster patent cliff fall to hit in the next four years and even one of the world's newest blockbusters is not safe

More News
Pharma in Focus

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 
Not a member? Sign up here
Pharma in Focus